Literature DB >> 10507595

The patient-related costs of care for sepsis patients in a United Kingdom adult general intensive care unit.

D L Edbrooke1, C L Hibbert, J M Kingsley, S Smith, N M Bright, J M Quinn.   

Abstract

OBJECTIVE: To determine the patient-related costs of care for critically ill patients with severe sepsis or early septic shock.
DESIGN: Retrospective, longitudinal, observational study during a 10-month period.
SETTING: Adult general intensive care unit (ICU) in a university hospital located in the United Kingdom. PATIENTS: The study population consisted of 213 patients admitted consecutively to the ICU during a 10-month period. Thirty-six patients were identified using standard definitions as having developed sepsis and analyzed by group (according to the day on which sepsis was diagnosed): Group 1 patients were septic at admission to ICU (n = 16); group 2 patients were septic on their second day in the ICU (n = 10); and group 3 patients developed sepsis after their second day in the ICU (n = 10). One hundred and seventy-seven ICU patients without sepsis were used as the comparative group (group 4).
INTERVENTIONS: None. MAIN
RESULTS: Patient-related costs of care, length of ICU stay, and ICU and hospital mortality rates were compiled. The median daily costs of care for patients in groups 1, 2, and 3 were $930.74 (interquartile range $851.59-$1,263.96); $814.47 ($650.89-$1,123.06), and $1,079.39 ($705.02-$1,295.96), respectively; these were significantly more than the group 4 patient's daily cost of $750.38 ($644.10-$908.55) (p < .01). The median total cost of treating the group 4 patients was $1,666.87 ($979.71-$2,772.03), significantly less than for the patients with sepsis (p < .01). The difference in total costs of care between the sepsis groups was also significant (p < .05), with a group 1 patient costing $3,801.55 ($1,865.28-$11,676.08), a group 2 patient costing $13,089.17 ($5,792.94-$22,235.18), and a group 3 patient costing $17,962.78 ($13,030.83-$28,546.73). Patients in groups 1, 2, and 3 stayed in the ICU for 3.3 days (1.3-11.3), 16.5 days (8.9-22), and 16.1 days (10.9-9), respectively. Significant differences were found among the three groups (p < 0.05), as well as between the patients with sepsis and those without (p < 0.001), whose median length of stay was 1.9 days (0.9-3.6). The ICU mortality rates were 50% each for groups 1 and 2, 60% for group 3, and 20% for group 4. Only one patient with sepsis and 16 patients without sepsis died in the hospital ward, producing overall mortality rates of 56% for group 1 and 29% for group 4.
CONCLUSIONS: Patients with severe sepsis or early septic shock had a high mortality rate, spent prolonged periods of time in the ICU, and were significantly more expensive to treat than nonsepsis ICU patients.

Entities:  

Mesh:

Year:  1999        PMID: 10507595     DOI: 10.1097/00003246-199909000-00010

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  22 in total

1.  Incidence of sepsis in hospitalized patients.

Authors:  Rui Moreno; Susana Afonso; Teresa Fevereiro
Journal:  Curr Infect Dis Rep       Date:  2006-09       Impact factor: 3.725

Review 2.  Antibiotic stewardship programmes in intensive care units: Why, how, and where are they leading us.

Authors:  Yu-Zhi Zhang; Suveer Singh
Journal:  World J Crit Care Med       Date:  2015-02-04

Review 3.  [The cost of sepsis].

Authors:  O Moerer; H Burchardi
Journal:  Anaesthesist       Date:  2006-06       Impact factor: 1.041

Review 4.  Meropenem: a review of its use in patients in intensive care.

Authors:  M Hurst; H M Lamb
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

Review 5.  Sepsis, severe sepsis and septic shock: changes in incidence, pathogens and outcomes.

Authors:  Greg S Martin
Journal:  Expert Rev Anti Infect Ther       Date:  2012-06       Impact factor: 5.091

6.  A national Infection in Critical Care Quality Improvement Programme for England: A survey of stakeholder priorities and preferences.

Authors: 
Journal:  J Intensive Care Soc       Date:  2016-02-01

Review 7.  Piperacillin/tazobactam: a pharmacoeconomic review of its use in moderate to severe bacterial infections.

Authors:  M Young; G L Plosker
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 8.  Economic aspects of severe sepsis: a review of intensive care unit costs, cost of illness and cost effectiveness of therapy.

Authors:  Hilmar Burchardi; Heinz Schneider
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 9.  Drotrecogin alfa (activated): a pharmacoeconomic review of its use in severe sepsis.

Authors:  James E Frampton; Rachel H Foster
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

10.  A multicentre, prospective study to evaluate costs of septic patients in Brazilian intensive care units.

Authors:  Ana M C Sogayar; Flavia R Machado; Alvaro Rea-Neto; Amselmo Dornas; Cintia M C Grion; Suzana M A Lobo; Bernardo R Tura; Carla L O Silva; Ruy G R Cal; Idal Beer; Vilto Michels; Jorge Safi; Marcia Kayath; Eliezer Silva
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.